BACKGROUND: Treatment of degenerated mitral bioprostheses with transcatheter mitral valve-in-valve (MVIV) implantation is increasingly used. The goal of this review was to evaluate the one-year outcomes of this therapy using the most recent evidence. METHODS: A MEDLINE, Cochrane database and SCOPUS search was performed of published observational studies involving patients undergoing transcatheter MVIV for degenerated bioprosthesis to determine procedural success, thirty-day and one-year survival. RESULTS: A total of 2,684 patients undergoing transcatheter MVIV were identified from five studies with mean age of 73-75 years, 57-63% female and Society for Thoracic Surgery (STS) risk score ranging from 9-13%. Procedural technical success ranged from 94-98%, with 1-3% rates of periprocedural death, 0-2% stroke and 1-5% risk of left ventricular outflow tract (LVOT) obstruction. Thirty-day post-procedure mean mitral prosthetic gradient ranged from 6-7 mmHg and residual mitral regurgitation was mild or less in 96-100% of patients. Thirty-day survival and one-year survival ranged from 93-97% and 83-89% respectively. CONCLUSIONS: Transcatheter MVIV is an effective treatment for structural degeneration of biologic mitral valve replacement with low complication rates and favorable one-year outcomes. Accordingly, MVIV should be considered as a reasonable alternative to re-do surgical mitral valve replacement in high risk patients with comorbidities. Further study of long-term outcomes of this treatment is needed. 2021 Annals of Cardiothoracic Surgery. All rights reserved.
BACKGROUND: Treatment of degenerated mitral bioprostheses with transcatheter mitral valve-in-valve (MVIV) implantation is increasingly used. The goal of this review was to evaluate the one-year outcomes of this therapy using the most recent evidence. METHODS: A MEDLINE, Cochrane database and SCOPUS search was performed of published observational studies involving patients undergoing transcatheter MVIV for degenerated bioprosthesis to determine procedural success, thirty-day and one-year survival. RESULTS: A total of 2,684 patients undergoing transcatheter MVIV were identified from five studies with mean age of 73-75 years, 57-63% female and Society for Thoracic Surgery (STS) risk score ranging from 9-13%. Procedural technical success ranged from 94-98%, with 1-3% rates of periprocedural death, 0-2% stroke and 1-5% risk of left ventricular outflow tract (LVOT) obstruction. Thirty-day post-procedure mean mitral prosthetic gradient ranged from 6-7 mmHg and residual mitral regurgitation was mild or less in 96-100% of patients. Thirty-day survival and one-year survival ranged from 93-97% and 83-89% respectively. CONCLUSIONS: Transcatheter MVIV is an effective treatment for structural degeneration of biologic mitral valve replacement with low complication rates and favorable one-year outcomes. Accordingly, MVIV should be considered as a reasonable alternative to re-do surgical mitral valve replacement in high risk patients with comorbidities. Further study of long-term outcomes of this treatment is needed. 2021 Annals of Cardiothoracic Surgery. All rights reserved.
Authors: Howard Balshem; Mark Helfand; Holger J Schünemann; Andrew D Oxman; Regina Kunz; Jan Brozek; Gunn E Vist; Yngve Falck-Ytter; Joerg Meerpohl; Susan Norris; Gordon H Guyatt Journal: J Clin Epidemiol Date: 2011-01-05 Impact factor: 6.437
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: Ann Intern Med Date: 2009-07-20 Impact factor: 25.391
Authors: Sung-Han Yoon; Brian K Whisenant; Sabine Bleiziffer; Victoria Delgado; Niklas Schofer; Lena Eschenbach; Buntaro Fujita; Rahul Sharma; Marco Ancona; Ermela Yzeiraj; Stefano Cannata; Colin Barker; James E Davies; Antonio H Frangieh; Florian Deuschl; Tomaz Podlesnikar; Masahiko Asami; Abhijeet Dhoble; Anthony Chyou; Jean-Bernard Masson; Harindra C Wijeysundera; Daniel J Blackman; Rajiv Rampat; Maurizio Taramasso; Enrique Gutierrez-Ibanes; Tarun Chakravarty; Guiherme F Attizzani; Tsuyoshi Kaneko; S Chiu Wong; Horst Sievert; Fabian Nietlispach; David Hildick-Smith; Luis Nombela-Franco; Lenard Conradi; Christian Hengstenberg; Michael J Reardon; Albert Markus Kasel; Simon Redwood; Antonio Colombo; Saibal Kar; Francesco Maisano; Stephan Windecker; Thomas Pilgrim; Stephan M Ensminger; Bernard D Prendergast; Joachim Schofer; Ulrich Schaefer; Jeroen J Bax; Azeem Latib; Raj R Makkar Journal: J Am Coll Cardiol Date: 2017-08-29 Impact factor: 24.094
Authors: Michael W Cullen; Allison K Cabalka; Oluseun O Alli; Sorin V Pislaru; Paul Sorajja; Vuyisile T Nkomo; Joseph F Malouf; Frank Cetta; Donald J Hagler; Charanjit S Rihal Journal: JACC Cardiovasc Interv Date: 2013-05-15 Impact factor: 11.195
Authors: Anson Cheung; John G Webb; Marco Barbanti; Melanie Freeman; Ronald K Binder; Christopher Thompson; David A Wood; Jian Ye Journal: J Am Coll Cardiol Date: 2013-02-28 Impact factor: 24.094
Authors: Matheus Simonato; Brian Whisenant; Henrique Barbosa Ribeiro; John G Webb; Ran Kornowski; Mayra Guerrero; Harindra Wijeysundera; Lars Søndergaard; Ole De Backer; Pedro Villablanca; Charanjit Rihal; Mackram Eleid; Jörg Kempfert; Axel Unbehaun; Magdalena Erlebach; Filip Casselman; Matti Adam; Matteo Montorfano; Marco Ancona; Francesco Saia; Timm Ubben; Felix Meincke; Massimo Napodano; Pablo Codner; Joachim Schofer; Marc Pelletier; Anson Cheung; Mony Shuvy; José Honório Palma; Diego Felipe Gaia; Alison Duncan; David Hildick-Smith; Verena Veulemans; Jan-Malte Sinning; Yaron Arbel; Luca Testa; Arend de Weger; Helene Eltchaninoff; Thibault Hemery; Uri Landes; Didier Tchetche; Nicolas Dumonteil; Josep Rodés-Cabau; Won-Keun Kim; Konstantinos Spargias; Panagiota Kourkoveli; Ori Ben-Yehuda; Rui Campante Teles; Marco Barbanti; Claudia Fiorina; Arun Thukkani; G Burkhard Mackensen; Noah Jones; Patrizia Presbitero; Anna Sonia Petronio; Abdelhakim Allali; Didier Champagnac; Sabine Bleiziffer; Tanja Rudolph; Alessandro Iadanza; Stefano Salizzoni; Marco Agrifoglio; Luis Nombela-Franco; Nikolaos Bonaros; Malek Kass; Giuseppe Bruschi; Nicolas Amabile; Adnan Chhatriwalla; Antonio Messina; Sameer A Hirji; Martin Andreas; Robert Welsh; Wolfgang Schoels; Farrel Hellig; Stephan Windecker; Stefan Stortecky; Francesco Maisano; Gregg W Stone; Danny Dvir Journal: Circulation Date: 2020-09-25 Impact factor: 29.690